

## GLOBAL HEALTHCARE EXECUTIVE SUMMIT

LUNCH &  
WELCOME12:00 - 1:00 pm **Buffet Lunch** (*Ballroom/Lounge*)1:00 - 1:30 pm **Welcome & Introduction**  
Banks Bourne, Bourne Partners1:30 - 2:10 pm **"Spec Pharma & Consumer Health - One's Hot & One's Not"**  
*Moderator:* Jeremy Johnson, Bourne Partners  
Rich Baxter, Hayfin Capital Management LLP  
Jefferson Gregory, Gregory Pharmaceutical Holdings (GPH)  
Bill Humphries, Ortho Dermatologics - Valeant Pharmaceuticals  
Dan Spira, iNova Pharmaceuticals2:10 - 2:40 pm **Break #1**2:40 - 3:00 pm **"Healthcare Policy in the Era of #FakeNews"**  
*Introduction:* Jennifer Meyers, Marwood Group  
*Speaker:* Stephen Williams, Marwood Group3:00 - 3:40 pm **"Outsourcing Services - Driving Long-Term Efficiency & Value"**  
*Introduction:* Xan Smith, Bourne Partners  
*Moderator:* David Chapin, Forma Life Science Marketing  
David Crane, National Surgical Healthcare  
Bhooshi DeSilva, PPD Inc.  
Wendy Shusko, WellSpring Pharmaceutical Corp.  
Patrick Walsh, Avista Pharma Solutions3:40 - 4:00 pm **"Capital Markets from the Driver's Seat"**  
*Introduction:* Minor Hinson, Bourne Partners  
*Speaker:* Andrew Callaway, Bank of America Merrill Lynch4:00 - 4:30 pm **Break #2**4:30 - 4:50 pm **"Private Equity Perspectives"**  
*Introduction:* Minor Hinson, Bourne Partners  
*Speaker:* John Gammage, JPMorgan Chase & Co.4:50 - 5:30 pm **"A \$1.6 Billion CDMO Take Private Transaction - AMRI"**  
*Moderator:* Banks Bourne, Bourne Partners  
William Marth, Albany Molecular Research, Inc. (AMRI)  
William McMullan, The Carlyle GroupSPEAKERS &  
PANELISTSCOCKTAIL  
RECEPTION5:30 - 7:30 pm **Networking Cocktail Reception** (*Pavilion Terrace*)

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

\* listed by order of appearance

## Banks Bourne

*Senior Managing Director & Chief Executive Officer, Bourne Partners*

Banks Bourne is the Chief Executive Officer and Senior Managing Director of Bourne Partners. As CEO, Banks oversees all business operations and direct investment opportunities at the firm. Prior to founding Bourne Partners, he held the position of Senior Vice President of Corporate Development for TITAN Technology Partners and also worked in the Investment Banking division for Wachovia Securities, Inc.

He received a B.A. in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO) and serves on a number of boards.

Over the years, Banks has derived satisfaction by offering focused advisory services to healthcare and consumer oriented companies that need strategic, transactional and operational help; but knowing that his work has helped companies to improve the health and well-being of patients across the world is what continues to be most gratifying. He got his start in healthcare by investing in King Pharmaceuticals in the late 1990's and has not looked back since.

## Jeremy Johnson

*Managing Director, Bourne Partners*

Jeremy began his career as Director of Business Development with an Internet Incubator, VentureWorx. He then worked as a Founder and Managing Director at Madison Keats, a life sciences strategy and consulting firm, prior to joining the team at Bourne Partners in 2006. With a B.A. degree in Economics from Georgetown University and 12 years of healthcare focused M&A and private equity experience, he currently serves as a Managing Director at Bourne Partners, managing the firm's pharmaceutical and consumer health advisory practice. His primary focuses include M&A, licensing and select capital raise assignments.

An avid triathlete – when he's not "running things" at Bourne, Jeremy is likely to be found running a marathon or training for his next Ironman. He also remains very active with Georgetown University where he is President of the local alumni club, interviews prospective students and is a member of the board of governors of the alumni association. He and his wife live with their three children in the neighborhood where he grew up.

Jeremy is very active in the community and was showcased in the January 2013 edition of Society Magazine after being named a Standout Charlottean of the Year by the Charlotte Chapter of the Cystic Fibrosis Foundation.

## Richard Baxter

*Managing Director, Hayfin Capital Management*

Richard Baxter joined Hayfin in 2013 and serves as a Managing Director. From 2011 to 2013, he was Co-Founder and Managing Director of New Health Capital Partners, a life sciences and health care special situations fund. Prior to forming New Health Capital Partners, Richard was a Managing Director and Co-Head of the Healthcare Group for the Drawbridge Special Opportunities Fund at Fortress Investment Group from 2004 through 2010.

Richard's previous experience includes: Chief Business Officer of Concurrent Pharmaceuticals, Inc. and Vice President of Marketing and Business Development at ViroPharma Incorporated. He was also Head of Marketing and Business Development for PathoGenesis Corporation.

Richard began his career in healthcare in various marketing, sales and strategic planning positions at SmithKline Beecham Pharmaceuticals after serving as a financial analyst at Goldman, Sachs & Co.

He holds an MBA from Harvard Business School and an AB, cum laude, from Princeton University.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Jefferson J. Gregory

*Vice Chairman - Board of Directors, Gregory Pharmaceutical Holdings, Inc. (GPH)*

Jefferson Gregory graduated from the University of Maryland in 1979 with a BS degree in Pharmacy and from the University of Maryland in 1985 with a Juris Doctorate Degree.

Along with his brothers, Jefferson founded King Pharmaceuticals, Inc. in 1993. Jefferson served as President of King from 1993 through April 2002. Mr. Gregory also served on the Board of Directors for King Pharmaceuticals from 1994 until his resignation in May 2004. During his tenure as Chairman and CEO, King Pharmaceuticals' net revenue rose from approximately \$870.0 Million to over \$1.5 Billion.

Jefferson formed Graceway Pharmaceuticals in early 2006 through a partnership with GTCR Golder Rauner. As a result of that partnership, on December 29, 2006 Graceway acquired the U.S., Canadian and Latin American Operations of 3M Company's Branded Pharmaceutical Business and its leading dermatological product, Aldara® (imiquimod) Cream 5% in a series of complex transactions totaling \$1 Billion.

In January 2014, Jefferson, along with his brothers, co-founded Gregory Pharmaceutical Holdings, LLC (GPH). GPH owns UPM Pharmaceuticals and Nutrition and Fitness, Inc. (NFI). Jefferson serves as the Chairman, Board of Managers for NFI.

Jefferson has been happily married to Terri Dawn White-Gregory since October 12, 1991 and they have been blessed by two sons, Jordan and Jamison.

## William D. Humphries

*Executive Vice President & Company Group Chairman, Ortho Dermatologics - Valeant Pharmaceuticals (NYSE:VRX, TSX:VRX)*

Bill Humphries joined Valeant Pharmaceuticals in January 2017 as Executive Vice President, Company Group Chairman for Dermatology and OraPharma. Bill has more than 30 years of experience in the specialty pharmaceutical industry, with more than 26 of those years focused on the commercialization of dermatology specialty pharmaceutical products globally.

Previously, Bill was appointed CEO of Merz North America in March 2012, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals, LLC, Merz Aesthetics, Inc. and Merz Pharma Canada, Ltd. Bill also served on the Merz Pharma Board and was the Chairman of the Merz, Inc. Board of Directors.

Prior to joining Merz, Bill served as the President of Stiefel, and led the global integration of Stiefel into GlaxoSmithKline. In August 2009, Bill was appointed President of Stiefel, a GSK company, after GlaxoSmithKline (GSK) successfully acquired Stiefel Laboratories. Bill was a key leader in this transaction and the commercial lead for the global integration of Stiefel into GSK. From April 2008 to August 2009, Bill served as President of Stiefel Laboratories. Previously, Bill was Senior Vice President, US Commercial Operations and Chief Commercial Officer. Beginning in April 2006, he served as a member of the company's Board of Directors. Bill was a key leader in two major acquisitions for Stiefel: Barrier Therapeutics, Inc., which completed in 2008, and Connetics Corporation, which completed in 2006. From 1996 to 2004, Bill served in numerous executive roles in sales and marketing, business development, and international marketing for Allergan, Inc. He completed his tenure with Allergan, Inc. as Vice President US Skin Care.

Bill currently serves on the Board of Clearside Biomedical, is the Chair of the North Carolina State University Global Luxury Management Board and serves on the Aclaris Therapeutics Board. Bill received a Master's degree in Business Administration from Pepperdine University in Malibu, California. He completed his undergraduate studies at Bucknell University in Lewisburg, Pennsylvania, earning a Bachelor of Arts degree.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Dan Spira

*Chief Executive Officer, iNova Pharmaceuticals*

Dan Spira is the CEO of iNova Pharmaceuticals which is a leading Asia Pacific and Africa based Consumer Healthcare and Prescription products business. iNova operates across more than 15 countries and has leading market positions in Australia and South Africa as well as an established platform in Asia. iNova's diversified portfolio of products span areas such as weight management, dermatology, pain management, cardiology, OTC cough & cold and skincare. Dan has had extensive global experience across the Healthcare and Consumer Goods industries and within the supermarket, pharmacy, medical and hospital channels.

Dan was formerly a Vice President at Valeant Pharmaceuticals / Bausch + Lomb from 2011 to 2015, where he was responsible for leading a portfolio of North American businesses across Professional Skincare, Aesthetic Medicine and Eye Health. These Valeant owned companies included; Obagi Medical, Solta Medical, Laboratoire Dr Renaud, Bausch + Lomb Advanced Vision Products, Unilens Corp, Alden Optical Laboratories and Paragon Vision Sciences. Dan initially joined Valeant in 2011 as the President & Managing Director of the Valeant Pharmaceuticals International Group of Companies across the Australia and New Zealand markets.

Prior to Valeant, Dan spent over 15 years at Johnson & Johnson progressing through a range of sales, marketing and general management roles (local and regional) across Asia Pacific, Europe and North America. He served as Vice President of Marketing and Chief Marketing Officer for the Johnson & Johnson Consumer Group across Australia and New Zealand and his last role at J&J was as Vice President for the Beauty & Baby-care Global Business Units in the Pacific region.

## Jennifer Meyers

*Director, Marwood Group*

Ms. Meyers is a senior member of Marwood's Advisory Group where she advises executive management teams and investors in the healthcare sector. She provides consulting services to clients as they evaluate acquisitions, new geographic markets and service lines, regulatory and policy matters as well as other strategic initiatives. Her prior experience includes working extensively with privately held and publicly traded companies on a broad range of financial advisory transactions, including buy-sides, sell-sides, and corporate divestitures across a variety of healthcare sectors. As an investment banker, Ms. Meyers has closed over 30 transactions totaling more than \$32 billion in aggregate value.

Prior to joining Marwood, Ms. Meyers was a Principal in Healthcare Investment Banking at Morgan Joseph TriArtisan and at Bank of America Merrill Lynch, where she served as a senior member of the firm's M&A Group and primarily focused on transactions across the healthcare spectrum. Previously, she held positions at JPMorgan Securities in the M&A Group; Prestwick Scientific Capital, a private biopharmaceutical company focused on early-stage treatments and technologies; CrossHill Financial Group, a boutique investment bank; and America's Community Bankers, a national banking trade association. Ms. Meyers received a Bachelor of Science cum laude in Business Administration from the University of North Carolina at Chapel Hill and an MBA from Vanderbilt University.

## Stephen Williams, PhD

*Director, Marwood Group*

Stephen Williams has led Marwood's Life Sciences practice since 2010, and focuses on medical products – including drugs, biologics, medical devices and diagnostic tests.

Prior to joining the Marwood Group, Dr. Williams was an investment banker focused on healthcare companies. He was engaged in helping both privately held and publicly traded companies raise growth capital and develop business development strategies. Prior to that, he was an equity analyst covering the U.S. and European pharmaceutical and biotech companies.

Prior to working in the financial sector, Dr. Williams was a biomedical researcher and has held faculty positions at Vanderbilt University and Baylor College of Medicine, where he was the principal investigator on a NIH funded study. He holds a PhD in pharmacology from London University and an MBA from George Washington University.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Xan Smith

*Managing Director of Business Development, Bourne Partners*

Xan serves as Managing Director of Business Development at Bourne Partners. He is responsible for all business development activities, with a focus on M&A, capital raise, licensing and partnering opportunities within Bourne Partners' pharmaceutical and consumer health advisory practice.

Xan Smith began his career in Corporate Banking at Wachovia Securities. Prior to Bourne Partners, he worked in Investment Banking at First Union Capital Markets where he was responsible for corporate finance solutions for select industry and Fortune 1000 clients. Most recently, he served as a Director of Scale Finance LLC where he provided capital and strategic advisory solutions for venture stage growth companies in high growth sectors. His professional experience also includes extensive involvement in real estate development, both with large scale master planned community developer, Crescent Resources, LLC/Morgan Stanley Real Estate, and as a principal in his own development firm.

He received a B.A. in English and a Minor in Business from Wake Forest University (cum laude), and spent an academic year abroad at The University of St. Andrews, Scotland. He also received an M.B.A. degree from Wake Forest University.

## David Chapin

*Chief Executive Officer & Co-Founder, Forma Life Science Marketing & Forma Medical Device Design*

For nearly 30 years, David has provided strategic and tactical marketing expertise in the pre-clinical and clinical research, drug development, medical device and life science sectors. He has a keen understanding of scientific and medical concepts and a proven ability to translate them in ways that improve employee alignment and profit. These can be applied to communications of all types, including lead generation campaigns, content marketing and other thought leadership initiatives, websites, video, brochures, and more.

David presents to diverse audiences – from C-Suite executives, to researchers, to other technically sophisticated directors and managers – about the challenges of employee alignment and marketing/communication in the life sciences. His recent engagements include presentations about creating high-performance marketing for the North Carolina Center of Innovation, Virginia Bio, Charlottesville Business Innovation Council (VA), and MAGI East 2015 Clinical Research Conference. He has also taught and lectured at the Business / Innovation / Growth Council in Charlotte, NC, and several universities and colleges including the College of Design at North Carolina State University, the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill, UNC-Charlotte, East Carolina University, and Peace College. He was invited to speak at the South Carolina Arts Commission's first biennial, state-wide design arts conference entitled "Good Design is Good Business."

David is the author of "Making the Complex Compelling: Creating High Performance Marketing in the Life Sciences," and has been published in Life Science Leader, Impact, and PharmaExec magazines, as well as MedAd News.

David has a bachelor's degree in Physics, with a minor in Mathematics and Engineering from Swarthmore College, and a master's degree in Product Design from NC State University.

## Wendy Shusko

*Chief Executive Officer, WellSpring Pharmaceutical Corporation*

Wendy Shusko was a founding member of WellSpring Pharmaceutical Corporation which began operations in 2000. Over the past 17 years, WellSpring has focused on Specialty Pharma, OTC and Consumer Healthcare as well as Contract Manufacturing Services. She now serves as CEO of WellSpring.

Wendy has over 25 years of management experience within the Pharmaceutical industry with a focus on specialty pharmaceutical, consumer products, acquisition transactions from evaluation to implementation, and pharmaceutical manufacturing services.

Ms. Shusko is a New Jersey certified public accountant and holds a bachelor's degree in Accounting from the University of North Carolina. She currently resides with her husband Bob in Sarasota, Florida.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## David Crane

*Former Chairman & Chief Executive Officer, National Surgical Healthcare*

David Crane is the former Chairman and Chief Executive Officer of National Surgical Healthcare (NSH), an owner and operator of orthopedic focused surgical facilities. From 2012 to 2017, he grew the company from \$40 million EBITDA to greater than \$100 million. In May of 2017 he led and orchestrated the successful sale of NSH to Surgery Partners, Inc (SGRY) yielding a CAGR on initial investment of 19% and a greater than 3x total return.

David Crane was formerly a Senior Advisor of Irving Place Capital, a leading institutional private equity firm focused on making investments in middle-market companies. Prior to joining Irving Place Capital in 2008, Mr. Crane served as co-founder and CEO of NewHope Bariatrics, a company that operates ambulatory surgery centers that serve the needs of the morbidly obese. He raised \$18.5M of Debt and Equity Capital and developed facilities in Kansas City, Los Angeles and Dallas.

Previously, Mr. Crane spent 15 years as first COO and then CEO of MedCath Inc., a developer of physician joint-ventured heart hospitals throughout the U.S. Prior to joining MedCath, he served as COO of MediVision Incorporated, a Bain Capital-backed start-up that built and managed physician partnered ambulatory surgical centers. The company, which grew organically as well as through acquisition, was sold to Medical Care International in 1989 achieving strong double digit returns for the investors. From 1982 to 1985, he was a consultant and then a manager at Bain & Company.

Mr. Crane holds a B.A. from Yale College and an M.B.A. from the Harvard Business School.

## Bhooshi DeSilva

*Senior Vice President Corporate Development & Strategy, PPD, Inc.*

Bhooshi DeSilva joined PPD as Senior Vice President of Corporate Development and Strategy in 2014. In this role, he serves as a member of PPD's executive leadership team, leading the strategy, corporate development (M&A, Partnerships), enterprise data and innovation functions.

He partners with the senior leadership team on key strategic initiatives, leads PPD's data and disruptive innovation priorities, and plays an important role in driving PPD's evolution and growth. Since joining PPD, Bhooshi has led the organization in completing several strategic partnerships and acquisitions, and in strengthening and expanding the company's capabilities in priority focus areas.

Prior to joining PPD, Bhooshi had spent 15 years in the biopharmaceutical industry where he held several leadership positions. He started his career at Pfizer, where his roles spanned R&D portfolio management, U.S. commercial development, and U.S. customer strategy and negotiations. In 2009, Bhooshi was named vice president of business development evaluation and strategy, leading a team in the evaluation of licensing, acquisitions and corporate strategic initiatives for Pfizer. Later, he was head of corporate development, corporate strategy and head of International at Optimer Pharmaceuticals. Bhooshi played an integral role in the commercialization strategy and Optimer's sale to Cubist Pharmaceuticals in 2013. He brings an impressive track record of achievements in corporate strategic initiatives and M&A transactions on both the buy and sell sides.

Bhooshi holds degrees in finance, economics and engineering from Stanford University, London School of Economics and Imperial College of Science & Technology in London, U.K.



# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Patrick Walsh

*Chief Executive Officer, Avista Pharma Solutions*

Patrick Walsh is CEO of Avista Pharma Solutions, a high-growth CDMO that provides pharmaceutical clients with a full suite of service offerings including analytical, microbiology, API, formulation, drug sub-stance and drug product manufacturing expertise and capabilities.

Patrick has more than 30 years of experience building high achieving contract development and manufacturing organizations serving the pharmaceutical industry. His expertise directing pharmaceutical manufacturing operations on a global scale in parenteral, API, specialty pharmaceutical, formulation and analytical has delivered stellar value to clients and investors alike.

Prior to joining Avista Pharma, Patrick was CEO of AAIPharma Services, where he led its successful growth strategy that culminated in the company's sale for a 4.6 times return on invested capital. Prior to that, he was President & COO of Gen-sia-Sicor, where he led the company's growth from \$24 million to over \$600 million and facilitated its eventual sale to Teva for \$3.4 billion. Earlier in his career, he led U.S. & international business activities for Fujisawa USA. Patrick is also a founder of Diligence Team, LLC, a consulting firm to companies in the specialty pharma, development and manufacturing sectors.

Throughout his career, Patrick has focused on optimizing service, quality and team performance to drive success for customers, investors and stakeholders. Patrick has served as chairman, non-executive chairman and company director for 12 organizations as well as an executive advisor to private equity and venture capital firms.

## Minor Hinson

*Senior Managing Director & Chief Investment Officer, Bourne Partners*

Minor Hinson began his career in 1984 in Corporate Banking at NCNB/NationsBank/Bank of America and became a Senior Relationship Manager in the Baltimore/ Washington loan production office before deciding to attend business school in 1990. After an MBA internship in corporate finance at The Coca Cola Company in Atlanta, Minor accepted a position as an Associate at Bowles Hollowell Conner & Company in Charlotte. Minor left Bowles Hollowell to co-found The McMillan Group with former U.S. Congressman Alex McMillan. The McMillan Group was a corporate finance, investment and government lobby organization. Minor also worked as a Managing Principal at Piedmont Venture partners. Minor returned to Bank of America in 2002 to join the Strategic Investment and Alliances function that managed strategic investments across the bank's business lines, a function he eventually managed. He was then recruited to manage Corporate Development for the bank's Global Treasury Services (\$4 billion in profit). In 2007, Minor decided to join Christofferson Robb & Company to raise capital and work on the project team for the firm's \$800 million, U.K. based, offshore wind farm. After all the construction contracts were finalized, the project was sold to a private equity firm in 2008 and become the world's largest off-shore wind-farm post completion in 2011.

Minor Joined Bourne Partners in 2011. At Bourne Partners, Minor is responsible for direct investment and fund investing activities. Over the course of his career, he has completed more than \$5 billion in financial transactions. Minor received a B.A. in economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill.

## Andrew Callaway

*Managing Director - Global Head of Life Sciences, Bank of America Merrill Lynch (NYSE:BAC)*

Andrew Callaway is a senior member of the Life Sciences team in the Healthcare Corporate and Investment Banking Group at Bank of America Merrill Lynch. Andrew possesses nearly 20 years of investment banking experience and has advised on over 100 M&A and financing transactions in the biopharmaceutical sector.

Prior to joining Bank of America Merrill Lynch in the New York office in 2017, Andrew was the Global Head of Life Sciences Investment Banking at Wells Fargo and Deutsche Bank.

Andrew graduated from Amherst College. He is married with three children.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## John Gammage

*Vice Chairman of Investment Banking & Global Industry Head of the Financial Sponsor Coverage Group, JPMorgan Chase & Co. (NYSE:JPM)*

John Gammage is a Vice Chairman of Investment Banking, and Global Industry Head of the Financial Sponsor Coverage Group, JPMorgan's investment banking group targeting corporate finance and advisory opportunities with Private Equity Investment firms. His clients include The Carlyle Group, TPG Capital, Apax Partners, and Avista Capital.

John joined Manufacturers Hanover Trust Company in 1988. In 1989, after the completion of the bank's Management Training Program, John joined the bank's Merchant Banking Division originating structured financings for non-investment grade energy clients. In 1992, he joined Chemical Bank's Structured Finance Group, specializing in the structuring and syndication of leveraged buyout and recapitalization transactions.

In 1993, he joined the bank's Financial Sponsor Coverage Group. John managed JPMorgan's West Coast Financial Sponsor business from 2000-2002 before returning to New York.

John received a B.A. degree in Economics from Washington and Lee University and an M.B.A. degree with honors from Columbia Business School.

## William H. McMullan

*Principal with U.S. Buyout, The Carlyle Group (NASDAQ:CG)*

William H. McMullan is a Principal with U.S. Buyout, focusing on investments in the Healthcare sector. He is based in New York.

Since joining Carlyle, William has been actively involved in a number of Carlyle's investments including Albany Molecular Research, Inc, WelldyneRx, Rede D'Or São Luiz S.A., Grupo Qualicorp, Multiplan, Inc. and LifeCare Holdings, Inc.

Prior to joining Carlyle in 2007, William was with J.W. Childs Associates in Boston.

William received an M.B.A. from Harvard University and a B.S. in Economics with a minor in Computer Science from Duke University.

## William Marth

*President & Chief Executive Officer, Albany Molecular Research Inc. (AMRI)*

A director of the company since 2012, William Marth has served as President and Chief Executive Officer of AMRI since 2014. He also served as Chairman of the Board in 2013.

Prior to joining AMRI, William served as President and CEO of Teva Pharmaceutical Industries Ltd. in the Americas as well as CEO of Teva North America and Teva USA. In addition, he worked with several large equity firms providing guidance on their healthcare investments. He was a member of Teva's global executive management team from 2007 to 2012 and before that was Executive Vice President and Vice President of Sales and Marketing for Teva USA. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.

William earned a bachelor's in pharmacy from the University of Illinois and his M.B.A. from the Keller Graduate School of Management, DeVry University and an honorary D.H.L. from the Albany College of Pharmacy and Health Sciences. He is a pharmacist and is currently a director at Galmed and the University of Illinois at Chicago College of Pharmacy.

Previously, William served as the Chairman of the Board of the Generic Pharmaceutical Association and the American Society for Health-System Pharmacists, as well as on various boards and committees, including the University of the Sciences in Philadelphia and the board of ambassadors for Johns Hopkins Project RESTORE.